4.5 Article

Peroxisome proliferator-activated receptor-α agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function

Journal

EUROPEAN JOURNAL OF NEUROSCIENCE
Volume 33, Issue 8, Pages 1421-1432

Publisher

WILEY-BLACKWELL
DOI: 10.1111/j.1460-9568.2011.07637.x

Keywords

fenofibrate; nitric oxide; peroxisome; peroxisome proliferator activated receptor

Categories

Funding

  1. Multiple Sclerosis Society of Great Britain
  2. Multiple Sclerosis Society of Northern Ireland

Ask authors/readers for more resources

Inflammation is known to cause significant neuronal damage and axonal injury in many neurological disorders. Among the range of inflammatory mediators, nitric oxide is a potent neurotoxic agent. Recent evidence has suggested that cellular peroxisomes may be important in protecting neurons from inflammatory damage. To assess the influence of peroxisomal activation on nitric oxide-mediated neurotoxicity, we investigated the effects of the peroxisomal proliferator-activated receptor (PPAR)-alpha agonist fenofibrate on cortical neurons exposed to a nitric oxide donor or co-cultured with activated microglia. Fenofibrate protected neurons and axons against both nitric oxide donor-induced and microglia-derived nitric oxide-induced toxicity. Moreover, cortical neurons treated with this compound showed a significant increase in gene expression of ABCD3 (the gene encoding for peroxisomal membrane protein-70), with a concomitant increase in protein levels of PPAR-alpha and catalase, which was associated with a functional increase in the activity of this enzyme. Collectively, these observations provide evidence that modulation of PPAR-alpha activity and peroxisomal function by fenofibrate attenuates nitric oxide-mediated neuronal and axonal damage, suggesting a new therapeutic approach to protect against neurodegenerative changes associated with neuroinflammation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro

Juliana Redondo, Pamela Sarkar, Kevin Kemp, Paul F. Virgo, Joya Pawade, Aimie Norton, David C. Emery, Martin G. Guttridge, David I. Marks, Alastair Wilkins, Neil J. Scolding, Claire M. Rice

MULTIPLE SCLEROSIS JOURNAL (2018)

Article Clinical Neurology

Aberrant cerebellar Purkinje cell function repaired in vivo by fusion with infiltrating bone marrow-derived cells

Kevin C. Kemp, Rimi Dey, Johan Verhagen, Neil J. Scolding, Maria M. Usowicz, Alastair Wilkins

ACTA NEUROPATHOLOGICA (2018)

Article Medicine, General & Internal

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

J. William L. Brown, Alasdair Coles, Dana Horakova, Eva Havrdova, Guillermo Izquierdo, Alexandre Prat, Marc Girard, Pierre Duquette, Maria Trojano, Alessandra Lugaresi, Roberto Bergamaschi, Pierre Grammond, Raed Alroughani, Raymond Hupperts, Pamela McCombe, Vincent Van Pesch, Patrizia Sola, Diana Ferraro, Francois Grand'Maison, Murat Terzi, Jeannette Lechner-Scott, Schlomo Flechter, Mark Slee, Vahid Shaygannejad, Eugenio Pucci, Franco Granella, Vilija Jokubaitis, Mark Willis, Claire Rice, Neil Scolding, Alastair Wilkins, Owen R. Pearson, Tjalf Ziemssen, Michael Hutchinson, Katharine Harding, Joanne Jones, Christopher McGuigan, Helmut Butzkueven, Tomas Kalincik, Neil Robertson, Marco Onofrj, Giovanna De Luca, Valeria Di Tommaso, Daniela Travaglini, Erika Pietrolongo, Maria di Ioia, Deborah Farina, Luca Mancinelli, Suzanne Hodgkinson, Celia Oreja-Guevara, Cavit Boz, Julie Prevost, Javier Olascoaga, Bart Van Wijmeersch, Michael Barnett, Freek Verheul, Juan Ingacio Rojas, Daniele Spitaleri, Maria Edite Rio, Bruce Taylor, Jose Luis Sanchez-Menoyo, Cristina Ramo-Tello, Claudio Solaro, Tunde Csepany, Gerardo Iuliano, Olga Skibina, Thor Petersen, Ricardo Fernandez Bolanos, Youssef Sidhom, Riadh, Steve Vucic, Richard Macdonell, Angel Perez Sempere, Magdolna Simo, Ilya Kister, Neil Shuey, Radek, Jose Andres Dominguez, Maria Pia Amato, Maria Laura Saladino, Allan Kermode, Ernest Butler, Fraser Moore, Stella Hughes, Gavin McDonnell, Imre Piroska, Bassem Yamout, Aysun Soysal, Serkan Ozakbas, Cees Zwanikken

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Letter Clinical Neurology

Brain biopsy before or after treatment with corticosteroids?

Claire M. Rice, Shelley A. Renowden, Kathryn Urankar, Seth Love, Neil J. Scolding

NEURORADIOLOGY (2020)

Article Clinical Neurology

Maternal micro-chimeric cells in the multiple sclerosis brain

Heidi Snethen, Jody Ye, Kathleen M. Gillespie, Neil J. Scolding

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Article Clinical Neurology

KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis

Kelly Hares, K. Kemp, S. Loveless, C. M. Rice, N. Scolding, E. Tallantyre, N. Robertson, A. Wilkins

Summary: This study aimed to assess the prognostic value of KIF5A in MS and found that CSF KIF5A levels were positively correlated with MS disease severity, with progressive MS patients showing higher expression. Additionally, risk alleles of MS susceptibility gene loci were associated with relapse rates, treatment methods, and disease duration in MS patients. Further studies on analyzing MS susceptibility SNPs for prognostic value are recommended.

JOURNAL OF NEUROLOGY (2021)

Article Clinical Neurology

Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection

Pamela Sarkar, Juliana Redondo, Kelly Hares, Steven Bailey, Anastasia Georgievskaya, Kate Heesom, Kevin C. Kemp, Neil J. Scolding, Claire M. Rice

Summary: The study compared the secretome of MSC from control subjects and people with MS, showing that MSC from progressive MS have lower levels of mitochondrial fumarate hydratase. Exogenous mFH restored the neuroprotective potential of MS-MSC in vitro. Additionally, MS-MSC had reduced levels of fumarate hydratase with downstream effects on oxidative stress regulation.

MULTIPLE SCLEROSIS JOURNAL (2022)

Article Clinical Neurology

Repeat infusion of autologous bone marrow cells in progressive multiple sclerosis - A phase I extension study (SIAMMS II)

Claire M. Rice, Pamela Sarkar, Peter Walsh, Denise Owen, Clare Bidgood, Paul Smith, Nick M. Kane, Suhail Asghar, David I. Marks, Neil J. Scolding

Summary: This study demonstrates the safety and feasibility of repeated non-myeloablative autologous bone marrow-derived cell therapy in patients with progressive multiple sclerosis.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Editorial Material Clinical Neurology

Amyloid cerebrovasculopathies

N. J. Scolding

PRACTICAL NEUROLOGY (2022)

Article Multidisciplinary Sciences

An open-label pilot study of recombinant granulocyte-colony stimulating factor in Friedreich's ataxia

Kevin C. Kemp, Anastasia Georgievskaya, Kelly Hares, Juliana Redondo, Steven Bailey, Claire M. Rice, Neil J. Scolding, Chris Metcalfe, Alastair Wilkins

Summary: This pilot study investigates the potential therapeutic effects of recombinant granulocyte-colony stimulating factor (G-CSF) administration in patients with Friedreich's ataxia (FA). The findings demonstrate that G-CSF treatment is safe in FA patients, and it leads to mobilization of hematopoietic stem cells (HSCs) comparable to that of healthy individuals. Moreover, G-CSF administration results in sustained increases in cellular frataxin concentrations and elevated expression of PGC-1 alpha and Nrf2, indicating its potential clinical impact in FA patients.

NATURE COMMUNICATIONS (2022)

Article Clinical Neurology

Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why?

Gavin Brittain, Alasdair J. Coles, G. Giovannoni, Paolo Antonio Muraro, Jacqueline Palace, Jennifer Petrie, Elisa Roldan, N. J. Scolding, John A. Snowden, Basil Sharrack

Summary: In carefully selected patients, autologous HSCT is a safe and highly effective treatment for immune-mediated neurological disorders. Limited understanding has caused confusion, mistrust, and an increase in health tourism.

PRACTICAL NEUROLOGY (2023)

Article Clinical Neurology

Acute flaccid myelitis: not uncommon in rural Uganda?

Sam Olum, Charlotte Scolding, Venice Omona, Kansiime Jackson, Neil Scolding

Summary: Acute Flaccid Myelitis is a paralytic disease that mainly affects children and has similarities to poliomyelitis. It is an emerging, global, infectious neurological disease that has been rapidly spreading to different regions. However, it has been poorly studied in low- and middle-income countries due to a lack of research and neurological care services in these areas.

BRAIN COMMUNICATIONS (2023)

Article Surgery

Factors affecting mortality after traumatic brain injury in a resource-poor setting

R. Okidi, D. M. Ogwang, T. R. Okello, D. Ezati, W. Kyegombe, D. Nyeko, N. J. Scolding

BJS OPEN (2020)

Review Clinical Neurology

The diagnosis of primary central nervous system vasculitis

Claire M. Rice, Neil J. Scolding

PRACTICAL NEUROLOGY (2020)

No Data Available